Brain Scientific Inc. (BRSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Brain Scientific Inc. (BRSF) trades at $0.0006 with AI Score 49/100 (Grade C). Brain Scientific Inc. is a medtech company focused on neurology-based medical devices. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BRSF: BRSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BRSF: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Brain Scientific Inc. (BRSF) Healthcare & Pipeline Overview
Brain Scientific Inc. develops and markets neurology-focused medical devices, including the NeuroCap EEG system and NeuroNet Cloud platform. Operating in the competitive medical device sector, the company targets improved EEG technology and data analysis solutions for neurological applications, while navigating the challenges of a small-cap, OTC-listed entity.
What Is the Investment Thesis for BRSF?
Brain Scientific Inc. presents a speculative investment opportunity within the medical device sector. The company's NeuroCap and NeuroEEG products target the EEG market, offering potential improvements in usability and data analysis. With a market capitalization of $0.00B, the company is a micro-cap stock trading on the OTC market, implying higher risk and volatility. A key value driver is the potential adoption of NeuroCap and NeuroEEG by hospitals and clinics seeking more efficient EEG solutions. Growth catalysts include potential FDA approvals for new products and expansion of the NeuroNet Cloud platform. However, the company's negative profit margin of -5753.0% and reliance on OTC markets are significant risk factors. Investors should carefully consider the company's financial position and competitive landscape before investing.
Based on FMP financials and quantitative analysis
BRSF Key Highlights
- Market Cap of $0.00B reflects its micro-cap status and potential for high volatility.
- Gross Margin of 25.3% indicates the profitability of its products before operating expenses.
- Profit Margin of -5753.0% highlights significant challenges in achieving overall profitability.
- Beta of 0.36 suggests lower volatility compared to the overall market.
- Operates in the medical device industry, focusing on neurology-based solutions.
Who Are BRSF's Competitors?
BRSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.16 | +1.71% | $13.7M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.08 | -0.24% | $15.4M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.22 | +2.14% | $20.9M | 73 |
| PLSM PLSM | $3.51 | -8.12% | $22.8M | 60 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
| NVCN Neovasc Inc. | $30.03 | +0.00% | $82.9M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRSF's Key Strengths?
- Innovative NeuroCap design.
- NeuroNet Cloud platform for data analysis.
- Focus on neurology provides specialization.
- Proprietary technology and intellectual property.
What Are BRSF's Weaknesses?
- Small market capitalization and limited resources.
- Negative profit margin and financial instability.
- Reliance on OTC markets.
- Limited brand recognition.
What Could Drive BRSF Stock Higher?
- Potential FDA approvals for new products or enhancements to existing products.
- Expansion of the NeuroNet Cloud platform and its integration with other healthcare systems.
- Strategic partnerships with hospitals and clinics to expand market reach.
- International expansion into new markets.
- Development of new EEG applications beyond traditional diagnostics.
What Are the Key Risks for BRSF?
- Financial-distress signal — its Altman Z-Score of -6.81 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger, established medical device companies.
- Regulatory hurdles and compliance requirements for medical devices.
- Technological obsolescence and the emergence of competing technologies.
- Limited financial resources and negative profit margin.
- Reliance on OTC markets and the associated risks of limited liquidity and transparency.
What Are the Growth Opportunities for BRSF?
- Expansion of NeuroNet Cloud Platform: The NeuroNet Cloud platform offers a significant growth opportunity by providing data analytics and storage solutions for EEG data. The market for cloud-based healthcare solutions is expanding rapidly, driven by the increasing adoption of electronic health records and the need for data-driven insights. By expanding the capabilities of NeuroNet Cloud and integrating it with other healthcare systems, Brain Scientific can attract new customers and generate recurring revenue streams. Timeline: Ongoing, with continuous updates and feature additions planned.
- FDA Approvals for New Products: Obtaining FDA approvals for new products and enhancements to existing products is crucial for Brain Scientific's growth. Regulatory approvals validate the safety and efficacy of the company's devices, allowing them to be marketed and sold to healthcare providers. The timeline for FDA approvals can vary depending on the complexity of the device and the regulatory pathway chosen. Successful approvals can significantly boost the company's revenue and market share. Timeline: Ongoing, with submissions planned for various products.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Brain Scientific with access to a wider customer base and valuable feedback on its products. These partnerships can involve pilot programs, joint research projects, and co-marketing initiatives. By collaborating with healthcare providers, Brain Scientific can demonstrate the value of its products and build long-term relationships. Timeline: Ongoing, with active outreach to potential partners.
- International Expansion: Expanding into international markets represents a significant growth opportunity for Brain Scientific. The global market for medical devices is vast, and many countries have a growing need for advanced neurological solutions. By obtaining regulatory approvals in key international markets and establishing distribution networks, Brain Scientific can diversify its revenue streams and reduce its reliance on the US market. Timeline: Potential, with initial focus on select international markets.
- Development of New EEG Applications: Exploring new applications for EEG technology beyond traditional diagnostics can unlock new growth opportunities for Brain Scientific. This could involve developing EEG-based solutions for monitoring sleep disorders, assessing cognitive function, or providing neurofeedback therapy. By expanding the applications of its technology, Brain Scientific can reach new customer segments and establish itself as a leader in the field of EEG innovation. Timeline: Ongoing, with research and development efforts focused on new applications.
What Opportunities Does BRSF Have?
- Expansion of NeuroNet Cloud platform.
- FDA approvals for new products.
- Strategic partnerships with hospitals and clinics.
- International expansion.
What Threats Does BRSF Face?
- Competition from larger, established medical device companies.
- Regulatory hurdles and compliance requirements.
- Technological obsolescence.
- Economic downturn and reduced healthcare spending.
What Are BRSF's Competitive Advantages?
- Proprietary NeuroCap design offers potential advantages in usability and comfort.
- NeuroNet Cloud platform provides a data analytics and storage solution that can create customer stickiness.
- Focus on neurology provides specialization and expertise in a niche market.
- Intellectual property protection through patents and trademarks.
What Does BRSF Do?
Founded in 2013 and headquartered in Sarasota, Florida, Brain Scientific Inc. is a medtech company specializing in neurology-focused medical devices. The company's core mission is to innovate and provide advanced solutions for the diagnosis and monitoring of neurological conditions. Its key product, NeuroCap, is a disposable EEG cap designed to improve the efficiency and accuracy of electroencephalography procedures. NeuroCap aims to address the limitations of traditional EEG systems by offering a more comfortable and user-friendly experience. Complementing NeuroCap is NeuroEEG, a clinical-grade device used to acquire, record, transmit, and display electrical brain activity in patients of all ages. The company also offers NeuroNet Cloud, a platform for storing and analyzing brain data, providing clinicians with tools for enhanced diagnostics and research. Beyond its neurology focus, Brain Scientific also develops motor platforms, including an ultra-precise micro dosing pump and other motion products. The company operates primarily in the United States, targeting hospitals, clinics, and research institutions. Brain Scientific's strategy centers on combining innovative hardware with data analytics to improve patient outcomes in neurology.
What Products and Services Does BRSF Offer?
- Develops and markets the NeuroCap, a disposable EEG cap designed for improved comfort and ease of use.
- Offers NeuroEEG, a clinical-grade device for recording and displaying electrical brain activity.
- Provides NeuroNet Cloud, a platform for storing and analyzing EEG data.
- Develops motor platforms, including micro dosing pumps.
- Focuses on neurology-based medical devices.
- Aims to improve the efficiency and accuracy of EEG procedures.
How Does BRSF Make Money?
- Sells NeuroCap and NeuroEEG devices to hospitals, clinics, and research institutions.
- Generates revenue from subscriptions to the NeuroNet Cloud platform.
- Potentially generates revenue from the sale of motor platforms and related products.
- Focuses on direct sales and partnerships with distributors.
What Industry Does BRSF Operate In?
Brain Scientific Inc. operates within the medical device industry, specifically targeting the neurology segment. The EEG market, in particular, is expected to grow as neurological disorders become more prevalent. Brain Scientific competes with larger, established medical device companies, as well as smaller, specialized firms. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products to healthcare providers.
Who Are BRSF's Key Customers?
- Hospitals
- Clinics
- Research institutions
- Neurologists
Brain Scientific Inc. (BRSF) Valuation Context
Relative to its peer group, BRSF's quantitative score of 49/100 is below the peer average of 65/100.
F-Score 3/9Financial Health
Brain Scientific Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.81 places it in the distress zone, a signal of elevated financial risk.
BRSF Financials
Bull Case vs Bear Case
Bull Case
- There's chatter about potential new partnerships brewing, which could significantly expand Brain Scientific's market reach.
- The community seems to be reacting positively to recent company communications, suggesting improved transparency.
- Insiders are holding steady, which could signal confidence in the company's long-term prospects.
- The general buzz is that Brain Scientific is innovating in a space with growing demand.
Bear Case
- Concerns are surfacing about the company's ability to scale production to meet potential demand.
- Some in the community are questioning the sustainability of their current business model.
- Recent market developments have increased scrutiny on smaller cap companies like Brain Scientific.
- There's been a noticeable uptick in negative sentiment related to competitor activity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BRSF Latest News
No recent news available for BRSF.
BRSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRSF.
Price Targets
Wall Street price target analysis for BRSF.
BRSF MoonshotScore
What does this score mean?
The MoonshotScore rates BRSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Hassan Kotob
CEO
Hassan Kotob serves as the CEO of Brain Scientific Inc. His background includes experience in managing and growing technology-focused companies. He has a track record of leading teams and driving innovation in the medical device sector. Kotob's expertise spans strategic planning, product development, and market expansion. He is responsible for overseeing all aspects of Brain Scientific's operations and executing the company's growth strategy. His leadership is focused on advancing the company's neurology-focused medical devices and expanding its market presence.
Track Record: Under Hassan Kotob's leadership, Brain Scientific has focused on developing and commercializing its NeuroCap and NeuroEEG products. Key milestones include the launch of the NeuroNet Cloud platform and efforts to secure regulatory approvals for new products. Kotob has also overseen the company's strategic partnerships and market expansion initiatives. His focus has been on driving innovation and building a strong foundation for future growth.
BRSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Brain Scientific Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the increased risk of fraud and manipulation. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher risk of fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile and disclosure statements.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings against the company.
- Development of proprietary technology (NeuroCap and NeuroNet Cloud).
- Focus on a specific niche market (neurology).
- Presence of a CEO with relevant experience.
- Company headquarters in the United States.
- Efforts to secure regulatory approvals for its products.
Brain Scientific Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for BRSF?
BRSF holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Brain Scientific Inc. is a medtech company focused on neurology-based medical devices. Their key product offerings include the NeuroCap EEG system and NeuroNet Cloud data platform.
What does Brain Scientific Inc. do?
Brain Scientific Inc. is a medtech company that develops and markets neurology-focused medical devices. Its primary product is the NeuroCap, a disposable EEG cap designed to improve the efficiency and accuracy of electroencephalography (EEG) procedures. The company also offers NeuroEEG, a clinical-grade device for recording brain activity, and NeuroNet Cloud, a platform for storing and analyzing EEG data.
What do analysts say about BRSF stock?
As of 2026-03-17, there is no available analyst coverage for BRSF stock. Given its micro-cap status and listing on the OTC market, the stock is not widely followed by analysts. Investors should conduct their own due diligence and consider the company's financial position, growth prospects, and risk factors before investing.
What are the main risks for BRSF?
The main risks for Brain Scientific Inc. include competition from larger, established medical device companies, regulatory hurdles and compliance requirements, technological obsolescence, limited financial resources, and reliance on OTC markets. The company's negative profit margin and small market capitalization make it particularly vulnerable to financial instability.
How does Brain Scientific Inc. navigate regulatory approval processes?
Brain Scientific Inc. navigates regulatory approval processes, primarily with the FDA, by adhering to established guidelines and standards for medical devices. The company must demonstrate the safety and efficacy of its products through rigorous testing and clinical trials. The specific regulatory pathway depends on the classification of the device and its intended use.
What is Brain Scientific Inc.'s strategy for commercializing its NeuroCap technology?
Brain Scientific Inc.'s strategy for commercializing its NeuroCap technology involves a multi-pronged approach. This includes direct sales to hospitals, clinics, and research institutions, as well as partnerships with distributors to expand market reach. The company also focuses on demonstrating the value proposition of NeuroCap through pilot programs and clinical studies.
What are the key factors to evaluate for BRSF?
Brain Scientific Inc. (BRSF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does BRSF data refresh on this page?
BRSF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BRSF's recent stock price performance?
Brain Scientific Inc. (BRSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative NeuroCap design. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.